Evidence map›Paper›PMID 32220235›Full record

ArticleAlzheimer's research & therapy2020

Beneficial association of angiotensin-converting enzyme inhibitors and statins on the occurrence of possible Alzheimer's disease after traumatic brain injury.

Mingfei Li, Joel Reisman, Benjamin Morris-Eppolito, Shirley X Qian, Lewis E Kazis, Benjamin Wolozin, Lee E Goldstein, Weiming Xia

Open access · goldAbstract read
In one paragraph

Article in Alzheimer's research & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. HMG-CoA Reductase Inhibitors for Traumatic Brain Injury.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023
    Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Clinical outcomes of COVID-19 infection among patients with Alzheimer's disease or mild cognitive impairment.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022
    Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Mingfei LiCenter for Healthcare Organization and Implementation Research, Edith Nourse Rogers Memorial Hospital, Bedford, MA, USA.
Joel ReismanCenter for Healthcare Organization and Implementation Research, Edith Nourse Rogers Memorial Hospital, Bedford, MA, USA.
Benjamin Morris-EppolitoGeriatric Research Education Clinical Center, Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA, 01730, USA.
Shirley X QianCenter for Healthcare Organization and Implementation Research, Edith Nourse Rogers Memorial Hospital, Bedford, MA, USA.
Lewis E KazisCenter for Healthcare Organization and Implementation Research, Edith Nourse Rogers Memorial Hospital, Bedford, MA, USA.
Benjamin WolozinDepartment of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.
Lee E GoldsteinDepartments of Radiology, Psychiatry, Neurology, and Pathology, Boston University School of Medicine, Boston, MA, USA.
Weiming XiaGeriatric Research Education Clinical Center, Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA, 01730, USA. weiming.xia@va.gov.
Boston University · USEdith Nourse Rogers Memorial Veterans Hospital · USMemorial Hospital · US

Funding

Big data and small molecules for Alzheimer's diseaseR01AG063913 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Weiming Xia · 2024 to 2026
$4.1M
Big data and small molecules for Alzheimer's diseaseRF1AG063913 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI GOLDSTEIN, LEE E., XIA, WEIMING · 2019 to 2021
$2.9M
Profiling Alzheimer's BiomarkersI01BX003527 · VA · EDITH NOURSE ROGERS MEMORIAL VETERANS HOSPITAL · PI XIA, WEIMING · 2018 to 2021
–
iPSC for Neurodegenerative DiseasesI21BX002215 · VA · EDITH NOURSE ROGERS MEMORIAL VETERANS HOSPITAL · PI XIA, WEIMING · 2015 to 2016
–
Three dimensional neuronal model for Alzheimer's brainI21BX003807 · VA · EDITH NOURSE ROGERS MEMORIAL VETERANS HOSPITAL · PI XIA, WEIMING · 2018 to 2019
–
BLRD VA I01 BX003527BLRD VA I01 BX004730BLRD VA I21 BX002215BLRD VA I21 BX003807NIA NIH HHS 1R01AG063913NIA NIH HHS R01 AG063913NIA NIH HHS RF1 AG063913U.S. Department of Veterans Affairs I21BX002215U.S. Department of Veterans Affairs I21BX003807U.S. Department of Veterans Affairs IO1 BX003527
6 · The paper itself

Abstract

backgroundPathological analysis of brain tissue from animals and humans with a history of traumatic brain injury (TBI) suggests that TBI could be one of the risk factors facilitating onset of dementia with possible Alzheimer's disease (AD), but medications to prevent or delay AD onset are not yet available.

methodsThis study explores four medication classes (angiotensin-converting enzyme inhibitors (ACEI), beta blockers, metformin, and statins) approved by the Food and Drug Administration (FDA) for other indications and evaluates their influence when used in combination on the risk of possible AD development for patients with a history of TBI. We identified patients with history of TBI from an existing Department of Veterans Affairs (VA) national database. Among 1,660,151 veterans who used VA services between the ages of 50 to 89 years old, we analyzed 733,920 patients, including 15,450 patients with a history of TBI and 718,470 non-TBI patients. The TBI patients were followed for up to 18.5 years, with an average of 7.7 ± 4.7 years, and onset of dementia with possible AD was recorded based on International Statistical Classification of Diseases (ICD) 9 or 10 codes. The effect of TBI on possible AD development was evaluated by multivariable logistic regression models adjusted by age, gender, race, and other comorbidities. The association of ACEI, beta blockers, metformin, statins, and combinations of these agents over time from the first occurrence of TBI to possible AD onset was assessed using Cox proportional hazard models adjusted for demographics and comorbidities.

resultsVeterans with at least two TBI occurrences by claims data were 25% (odds ratio (OR) = 1.25, 95% confidence intervals (CI) (1.13, 1.37)) more likely to develop dementia with possible AD, compared to those with no record of TBI. In multivariable logistic regression models (propensity score weighted or adjusted), veterans taking a combination of ACEI and statins had reduced risk in developing possible AD after suffering TBI, and use of this medication class combination was associated with a longer period between TBI occurring and dementia with possible AD onset, compared to patients who took statins alone or did not take any of the four target drugs after TBI.

conclusionsThe combination of ACEI and statins significantly lowered the risk of development of dementia with possible AD in a national cohort of people with a history of TBI, thus supporting a clinical approach to lowering the risk of dementia with possible AD.

Indexed as

Alzheimer DiseaseAngiotensin-Converting Enzyme InhibitorsBrain Injuries, TraumaticHydroxymethylglutaryl-CoA Reductase InhibitorsAgedAged, 80 and overCohort StudiesFemaleHumansMaleMiddle AgedRisk FactorsAngiotensin-Converting Enzyme InhibitorsHydroxymethylglutaryl-CoA Reductase InhibitorsAlzheimer’s diseaseAngiotensin-converting enzyme inhibitorsPreventionStatinsTraumatic brain injuryTreatment

Identifiers

PMID32220235
PMCPMC7102441
OpenAlexW3012965257

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.